Ranolazine Safely Decreases Ventricular and Atrial Fibrillation in Timothy Syndrome (LQT8)
Long QT eight (LQT8), otherwise known as Timothy syndrome (TS), is a genetic disorder causing hyper‐activation of the L‐type calcium channel Cav 1.2. This calcium load and the resultant increase in the QT interval provide the substrate for ventricular arrhythmias. We previously presented a case in a...
Gespeichert in:
| Veröffentlicht in: | Pacing and clinical electrophysiology 2012-03, Vol.35 (3), p.e62-e64 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e64 |
|---|---|
| container_issue | 3 |
| container_start_page | e62 |
| container_title | Pacing and clinical electrophysiology |
| container_volume | 35 |
| creator | SHAH, DIPAK P. BAEZ‐ESCUDERO, JOSE L. WEISBERG, IAN L. BESHAI, JOHN F. BURKE, MARTIN C. |
| description | Long QT eight (LQT8), otherwise known as Timothy syndrome (TS), is a genetic disorder causing hyper‐activation of the L‐type calcium channel Cav 1.2. This calcium load and the resultant increase in the QT interval provide the substrate for ventricular arrhythmias. We previously presented a case in a patient with TS who had a profound decrease in his burden of ventricular arrhythmias after institution of an L‐type calcium channel blocker. Although this patient's arrhythmia burden had decreased, he displayed an increasing burden of atrial fibrillation and still had bouts of ventricular fibrillation requiring defibrillator therapy. Basic research has recently shown that ranolazine, a multipotent ion‐channel blocker, may be of benefit in patients with LQT8 syndrome. This case report details the decrease of atrial fibrillation and ventricular fibrillation events in our LQT8 patient with the addition of ranolazine. (PACE 2010; 1–3) |
| doi_str_mv | 10.1111/j.1540-8159.2010.02913.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_926642940</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>926642940</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4353-c86de5e0b0617e49949fa00469009a05787c1bf9a2496d0bc4a536f022b39df43</originalsourceid><addsrcrecordid>eNqNkMlOwzAQhi0EgrK8AvINOKSMl6T2BakqZZEqsRUOXCwnmQhXWcBuBeHpSShwZi6z_bPoI4QyGLLOThdDFkuIFIv1kENXBa6ZGH5skMFfY5MMgMlRpITSO2Q3hAUAJCDjbbLDQSkRMz4gz_e2bkr76WqkD7bAsqXnmHm0AQN9wnrpXbYqrae2zum4y2xJL1zqXVnapWtq6mo6d1WzfGnpQ1vnvqmQHs_u5upkn2wVtgx48OP3yOPFdD65imY3l9eT8SzKpIhFlKkkxxghhYSNUGotdWEBZKIBtIV4pEYZSwttudRJDmkmbSySAjhPhc4LKfbI0Xrvq2_eVhiWpnIhw-7BGptVMJonieRaQqdUa2XmmxA8FubVu8r61jAwPVizMD0_0_MzPVjzDdZ8dKOHP0dWaYX53-AvyU5wtha8uxLbfy82t-PJtA_FFxrPheo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>926642940</pqid></control><display><type>article</type><title>Ranolazine Safely Decreases Ventricular and Atrial Fibrillation in Timothy Syndrome (LQT8)</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>SHAH, DIPAK P. ; BAEZ‐ESCUDERO, JOSE L. ; WEISBERG, IAN L. ; BESHAI, JOHN F. ; BURKE, MARTIN C.</creator><creatorcontrib>SHAH, DIPAK P. ; BAEZ‐ESCUDERO, JOSE L. ; WEISBERG, IAN L. ; BESHAI, JOHN F. ; BURKE, MARTIN C.</creatorcontrib><description>Long QT eight (LQT8), otherwise known as Timothy syndrome (TS), is a genetic disorder causing hyper‐activation of the L‐type calcium channel Cav 1.2. This calcium load and the resultant increase in the QT interval provide the substrate for ventricular arrhythmias. We previously presented a case in a patient with TS who had a profound decrease in his burden of ventricular arrhythmias after institution of an L‐type calcium channel blocker. Although this patient's arrhythmia burden had decreased, he displayed an increasing burden of atrial fibrillation and still had bouts of ventricular fibrillation requiring defibrillator therapy. Basic research has recently shown that ranolazine, a multipotent ion‐channel blocker, may be of benefit in patients with LQT8 syndrome. This case report details the decrease of atrial fibrillation and ventricular fibrillation events in our LQT8 patient with the addition of ranolazine. (PACE 2010; 1–3)</description><identifier>ISSN: 0147-8389</identifier><identifier>EISSN: 1540-8159</identifier><identifier>DOI: 10.1111/j.1540-8159.2010.02913.x</identifier><identifier>PMID: 20883512</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Acetanilides - therapeutic use ; Adult ; Anti-Arrhythmia Agents - therapeutic use ; Atrial Fibrillation - drug therapy ; Autistic Disorder ; Drug Therapy, Combination ; electrophysiology—clinical ; Humans ; long QT ; Long QT Syndrome - drug therapy ; Male ; pharmacology ; Piperazines - therapeutic use ; Ranolazine ; Syndactyly - drug therapy ; Treatment Outcome ; Ventricular Fibrillation - drug therapy ; Verapamil - therapeutic use</subject><ispartof>Pacing and clinical electrophysiology, 2012-03, Vol.35 (3), p.e62-e64</ispartof><rights>2010, The Authors. Journal compilation ©2010 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4353-c86de5e0b0617e49949fa00469009a05787c1bf9a2496d0bc4a536f022b39df43</citedby><cites>FETCH-LOGICAL-c4353-c86de5e0b0617e49949fa00469009a05787c1bf9a2496d0bc4a536f022b39df43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1540-8159.2010.02913.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1540-8159.2010.02913.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20883512$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SHAH, DIPAK P.</creatorcontrib><creatorcontrib>BAEZ‐ESCUDERO, JOSE L.</creatorcontrib><creatorcontrib>WEISBERG, IAN L.</creatorcontrib><creatorcontrib>BESHAI, JOHN F.</creatorcontrib><creatorcontrib>BURKE, MARTIN C.</creatorcontrib><title>Ranolazine Safely Decreases Ventricular and Atrial Fibrillation in Timothy Syndrome (LQT8)</title><title>Pacing and clinical electrophysiology</title><addtitle>Pacing Clin Electrophysiol</addtitle><description>Long QT eight (LQT8), otherwise known as Timothy syndrome (TS), is a genetic disorder causing hyper‐activation of the L‐type calcium channel Cav 1.2. This calcium load and the resultant increase in the QT interval provide the substrate for ventricular arrhythmias. We previously presented a case in a patient with TS who had a profound decrease in his burden of ventricular arrhythmias after institution of an L‐type calcium channel blocker. Although this patient's arrhythmia burden had decreased, he displayed an increasing burden of atrial fibrillation and still had bouts of ventricular fibrillation requiring defibrillator therapy. Basic research has recently shown that ranolazine, a multipotent ion‐channel blocker, may be of benefit in patients with LQT8 syndrome. This case report details the decrease of atrial fibrillation and ventricular fibrillation events in our LQT8 patient with the addition of ranolazine. (PACE 2010; 1–3)</description><subject>Acetanilides - therapeutic use</subject><subject>Adult</subject><subject>Anti-Arrhythmia Agents - therapeutic use</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Autistic Disorder</subject><subject>Drug Therapy, Combination</subject><subject>electrophysiology—clinical</subject><subject>Humans</subject><subject>long QT</subject><subject>Long QT Syndrome - drug therapy</subject><subject>Male</subject><subject>pharmacology</subject><subject>Piperazines - therapeutic use</subject><subject>Ranolazine</subject><subject>Syndactyly - drug therapy</subject><subject>Treatment Outcome</subject><subject>Ventricular Fibrillation - drug therapy</subject><subject>Verapamil - therapeutic use</subject><issn>0147-8389</issn><issn>1540-8159</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMlOwzAQhi0EgrK8AvINOKSMl6T2BakqZZEqsRUOXCwnmQhXWcBuBeHpSShwZi6z_bPoI4QyGLLOThdDFkuIFIv1kENXBa6ZGH5skMFfY5MMgMlRpITSO2Q3hAUAJCDjbbLDQSkRMz4gz_e2bkr76WqkD7bAsqXnmHm0AQN9wnrpXbYqrae2zum4y2xJL1zqXVnapWtq6mo6d1WzfGnpQ1vnvqmQHs_u5upkn2wVtgx48OP3yOPFdD65imY3l9eT8SzKpIhFlKkkxxghhYSNUGotdWEBZKIBtIV4pEYZSwttudRJDmkmbSySAjhPhc4LKfbI0Xrvq2_eVhiWpnIhw-7BGptVMJonieRaQqdUa2XmmxA8FubVu8r61jAwPVizMD0_0_MzPVjzDdZ8dKOHP0dWaYX53-AvyU5wtha8uxLbfy82t-PJtA_FFxrPheo</recordid><startdate>201203</startdate><enddate>201203</enddate><creator>SHAH, DIPAK P.</creator><creator>BAEZ‐ESCUDERO, JOSE L.</creator><creator>WEISBERG, IAN L.</creator><creator>BESHAI, JOHN F.</creator><creator>BURKE, MARTIN C.</creator><general>Blackwell Publishing Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201203</creationdate><title>Ranolazine Safely Decreases Ventricular and Atrial Fibrillation in Timothy Syndrome (LQT8)</title><author>SHAH, DIPAK P. ; BAEZ‐ESCUDERO, JOSE L. ; WEISBERG, IAN L. ; BESHAI, JOHN F. ; BURKE, MARTIN C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4353-c86de5e0b0617e49949fa00469009a05787c1bf9a2496d0bc4a536f022b39df43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Acetanilides - therapeutic use</topic><topic>Adult</topic><topic>Anti-Arrhythmia Agents - therapeutic use</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Autistic Disorder</topic><topic>Drug Therapy, Combination</topic><topic>electrophysiology—clinical</topic><topic>Humans</topic><topic>long QT</topic><topic>Long QT Syndrome - drug therapy</topic><topic>Male</topic><topic>pharmacology</topic><topic>Piperazines - therapeutic use</topic><topic>Ranolazine</topic><topic>Syndactyly - drug therapy</topic><topic>Treatment Outcome</topic><topic>Ventricular Fibrillation - drug therapy</topic><topic>Verapamil - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SHAH, DIPAK P.</creatorcontrib><creatorcontrib>BAEZ‐ESCUDERO, JOSE L.</creatorcontrib><creatorcontrib>WEISBERG, IAN L.</creatorcontrib><creatorcontrib>BESHAI, JOHN F.</creatorcontrib><creatorcontrib>BURKE, MARTIN C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pacing and clinical electrophysiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SHAH, DIPAK P.</au><au>BAEZ‐ESCUDERO, JOSE L.</au><au>WEISBERG, IAN L.</au><au>BESHAI, JOHN F.</au><au>BURKE, MARTIN C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ranolazine Safely Decreases Ventricular and Atrial Fibrillation in Timothy Syndrome (LQT8)</atitle><jtitle>Pacing and clinical electrophysiology</jtitle><addtitle>Pacing Clin Electrophysiol</addtitle><date>2012-03</date><risdate>2012</risdate><volume>35</volume><issue>3</issue><spage>e62</spage><epage>e64</epage><pages>e62-e64</pages><issn>0147-8389</issn><eissn>1540-8159</eissn><abstract>Long QT eight (LQT8), otherwise known as Timothy syndrome (TS), is a genetic disorder causing hyper‐activation of the L‐type calcium channel Cav 1.2. This calcium load and the resultant increase in the QT interval provide the substrate for ventricular arrhythmias. We previously presented a case in a patient with TS who had a profound decrease in his burden of ventricular arrhythmias after institution of an L‐type calcium channel blocker. Although this patient's arrhythmia burden had decreased, he displayed an increasing burden of atrial fibrillation and still had bouts of ventricular fibrillation requiring defibrillator therapy. Basic research has recently shown that ranolazine, a multipotent ion‐channel blocker, may be of benefit in patients with LQT8 syndrome. This case report details the decrease of atrial fibrillation and ventricular fibrillation events in our LQT8 patient with the addition of ranolazine. (PACE 2010; 1–3)</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>20883512</pmid><doi>10.1111/j.1540-8159.2010.02913.x</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0147-8389 |
| ispartof | Pacing and clinical electrophysiology, 2012-03, Vol.35 (3), p.e62-e64 |
| issn | 0147-8389 1540-8159 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_926642940 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Acetanilides - therapeutic use Adult Anti-Arrhythmia Agents - therapeutic use Atrial Fibrillation - drug therapy Autistic Disorder Drug Therapy, Combination electrophysiology—clinical Humans long QT Long QT Syndrome - drug therapy Male pharmacology Piperazines - therapeutic use Ranolazine Syndactyly - drug therapy Treatment Outcome Ventricular Fibrillation - drug therapy Verapamil - therapeutic use |
| title | Ranolazine Safely Decreases Ventricular and Atrial Fibrillation in Timothy Syndrome (LQT8) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T10%3A25%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ranolazine%20Safely%20Decreases%20Ventricular%20and%20Atrial%20Fibrillation%20in%20Timothy%20Syndrome%20(LQT8)&rft.jtitle=Pacing%20and%20clinical%20electrophysiology&rft.au=SHAH,%20DIPAK%20P.&rft.date=2012-03&rft.volume=35&rft.issue=3&rft.spage=e62&rft.epage=e64&rft.pages=e62-e64&rft.issn=0147-8389&rft.eissn=1540-8159&rft_id=info:doi/10.1111/j.1540-8159.2010.02913.x&rft_dat=%3Cproquest_cross%3E926642940%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=926642940&rft_id=info:pmid/20883512&rfr_iscdi=true |